New developments in antifungal strategy.
The increasing importance of invasive fungal infection as a cause of severe morbidity and mortality in immunocompromised patients has fuelled the development of new antifungal agents, including new triazole agents and echinocandins. Failure to diagnose fungal infection adequately has hampered the evaluation of these drugs in clinical trials. Consequently, the evidence base behind many prophylactic and empirical treatment strategies has been poor. Recent advances have improved diagnostic criteria and opened the way for more rational usage of these expensive preparations. The proven efficacy and improved safety profile of newer agents is a major advantage. Furthermore, better understanding of the immune response may allow novel strategies of adjunctive therapy and immunomodulation.
Shetty
Anjali
A
Department of Medical Microbiology, University Hospital of Wales, Heath Park, Cardiff, UK. anjalishettyuk@yahoo.co.uk
Barnes
Rosemary A
RA
D000935:Antifungal Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*
D000935:Antifungal Agents